Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis
Status:
Completed
Trial end date:
2020-07-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess secukinumab high dose (every 2 weeks) vs standard dose
(every 4 weeks) in heavy body weight subjects with moderate to severe plaque psoriasis.